Patents Assigned to Atengen, Inc.
  • Patent number: 11884647
    Abstract: The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: January 30, 2024
    Assignees: The Regents of the University of California, Atengen, Inc.
    Inventors: Hui Sun, Pu Sun, Guo Cheng, Adrian Chichuen Au, Ming Zhong